Dasatinibreview2021

Senescence and the SASP: many therapeutic avenues.

Genes & development

confidence

Key findings

Review of senescence and SASP regulation; no clinical or biological endpoints reported for dasatinib.

View source on PubMed (PMID 33262144) ↗

Sample size
N/A
Population
Not applicable (review article)
Dosing
N/A
Duration
N/A
Route
N/A
Blinding
not_reported
Controls
none
Drug class
senolytic
Full abstract

Cellular senescence is a stress response that elicits a permanent cell cycle arrest and triggers profound phenotypic changes such as the production of a bioactive secretome, referred to as the senescence-associated secretory phenotype (SASP). Acute senescence induction protects against cancer and limits fibrosis, but lingering senescent cells drive age-related disorders. Thus, targeting senescent cells to delay aging and limit dysfunction, known as "senotherapy," is gaining momentum. While drugs that selectively kill senescent cells, termed "senolytics" are a major focus, SASP-centered approaches are emerging as alternatives to target senescence-associated diseases. Here, we summarize the regulation and functions of the SASP and highlight the therapeutic potential of SASP modulation as complimentary or an alternative to current senolytic approaches.

Research information, not medical advice. StudyKit summarizes published studies to help you understand your protocol. It does not diagnose, treat, or replace a clinician. Talk to a qualified provider before changing anything you take.